3-methoxytyramine/dopamine ratio, as well as on VMAT2-specific binding in the striatum and the substantia nigra. Progesterone decreased MPTP effects on 3,4-dihydroxyphenylacetic acid concentrations and DAT-specific binding in the lateral part of the anterior striatum and in the middle striatum (medial and lateral parts). Progesterone treatment of intact mice had no effect on the markers investigated. For experiment 2, measures of dopaminergic markers in the striatum showed that 8 mg/kg of progesterone was the most effective dose to reduce MPTP effects, and more limited effects were observed with 16 mg/kg. We found that progesterone treatment increases the levels of brain progesterone itself as well as of its metabolites. Conclusion: Our result showed that progesterone has neuroprotective effects on dopaminergic neurons in MPTP-treated male mice.
Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder and is likely to increase due to the aging population. The major pathology in PD is the selective and progressive death of dopamine (DA) cell bodies in the substantia nigra. There is presently no cure for PD, and the most common treatments (levodopa and DA agonists) improve motor symptoms without preventing or delaying the degenerative process [1] . Nevertheless, as the disease progresses, these therapies eventually lose their effectiveness for many patients, and major motor complications, such as dyskinesia, often appear [1] . Therefore, neuroprotective compounds that could prevent the loss of DA neurons or reverse the progression of PD are urgently needed.
Several studies have reported that men are at greater risk of developing PD than women [2] [3] [4] , suggesting that ovarian hormones have a beneficial influence on the risk of developing PD. Animal models supported the neuroprotective effect of 17β-estradiol against the damage to the nigrostriatal neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice and by lesion with 6-hydroxydopamine (6-OHDA) in rats [5, 6] . The beneficial effect of progesterone (PROG) has been studied less than that of 17β-estradiol, but several animal and clinical studies have shown that PROG exerts a beneficial effect against brain damage. PROG has been reported to have protective effects on the dopaminergic terminals in mice expose to MPTP or methamphetamine [7] [8] [9] . Moreover, studies have highlighted that PROG has a beneficial effect when administered following traumatic brain injury, both in animal models and in humans [10] [11] [12] , but very recent clinical studies found no beneficial effects, which may be because of the complexity and heterogeneity of the disorder [13, 14] . There is presently no therapy (drug that slows, stops, or reverses disease progression) recognized to have a neuroprotective effect in PD patients [15, 16] , and PROG could be a good candidate for delaying the progression or rescuing neurons in PD patients.
The present study sought to extend our previous findings concerning the neuroprotective effect of a low dose of PROG (1 μg) [7, 9] . First, given that PROG is a neuromodulator [17] , we have differentiated the neuroprotective versus neuromodulatory effect of PROG on the DA system, by investigating and comparing the effect of PROG in intact, nonlesioned mice with that in MPTPtreated mice with measures of DA, DA transporter (DAT), and vesicular monoamine transporter 2 (VMAT2). In a second experiment, we investigated if high doses of PROG had the capacity to protect dopaminergic neurons that had been exposed to MPTP in male mice. Furthermore, we measured how plasma and brain levels of several neuroactive steroids are modulated following MPTP lesion and treatment with PROG.
Materials and Methods
Animals and Treatment C57BL/6 male mice (age 10 weeks) were purchased from Charles River Canada (Montreal, Que., Canada). MPTP and PROG were purchased from Sigma Chemical (St. Louis, Mo., USA). The Laval University Animal Care Committee approved all of the animal studies. All efforts were made to minimize animal suffering and to reduce the number of mice used.
Experiment 1
Each group of mice (average weight 24.33 ± 0.19 g) received treatment with PROG (1 μg, twice daily, s.c.) or vehicle (0.9% saline with 0.3% gelatin, twice daily, s.c.) for 10 days. On day 5, the mice received 4 intraperitoneal injections of MPTP (11 mg/kg) at 2-hour intervals, whereas the control groups received saline solution. This acute MPTP model induced a decrease of approximately 50% in the striatal DA concentration as well as in DAT-and VMAT2-specific binding in the striatum [18] . No change in tyrosine hydroxylase immunoreactivity is observed in the substantia nigra in this model [18] . On day 11, the mice were decapitated, and the brains were quickly removed and frozen in isopentane (-40 ° C).
Experiment 2
Mice (average weight 23.87 ± 0.12 g) received 4 intraperitoneal injections of MPTP (6.5 mg/kg) at 2-hour intervals, whereas the control groups received saline solution. A dose of PROG similar to that in neuroprotection experiment 1 (1 μg) was investigated under the conditions of experiment 2. One hour after the first MPTP injection, the mice received 1 intraperitoneal injection of PROG. One hour after the last injection of MPTP, the mice received 1 subcutaneous injection of PROG. During the following 5 days, the mice received 2 daily subcutaneous injections of PROG. For all the dopaminergic markers measured, this treatment regimen gave no or modest protective activity [our unpubl. results]. Hence, consistent with the reported rescue results with PROG in 6-OHDA rats [19, 20] , we used higher doses of PROG in the present experiment. One hour after the first MPTP injection, the mice received 1 intraperitoneal injection of PROG [8 mg/kg (191 μg per injection) or 16 mg/kg (382 μg per injection)]. One hour after the last injection of MPTP, the mice received 1 subcutaneous injection of PROG (8 or 16 mg/kg). During the following 5 days, the mice received 1 daily subcutaneous injection of PROG (8 or 16 mg/kg). On day 6, the mice were decapitated, and the brains were quickly removed and frozen in isopentane (-40 ° C).
Brain Preparation
One mouse brain hemisphere was used to measure DA markers and the other for steroid concentration analyses. A unilateral striatum was used to assay DA and its metabolite concentrations. The anterior (bregma 1.54 to 1.18 mm), middle (bregma 0.50 to 0.14 mm), and posterior striatum (bregma -0.34 to -0.70 mm) and the substantia nigra (bregma -2.80 to -3.88 mm) [21] of the contralateral hemisphere were cut on a cryostat in 12-μm slices. The slices were maintained at -80 ° C until assayed.
Striatal Biogenic Amine Determination
The left anterior striata were dissected, homogenized in 250 μl of 0.1 N HClO 4 at 4 ° C, and then centrifuged at 10,000 g for 10 min (4 ° C) to precipitate proteins. The concentrations of DA and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), 3-methoxytyramine (3-MT), and homovanillic acid (HVA), as well as serotonin and its metabolite 5-hydroxyindoleacetic acid (5-HIAA), were measured by high-performance liquid chromatography with electrochemical detection as we have previously described [7, 22, 23] . Supernatants of striatal tissue were directly injected into the chromatograph consisting of a Waters 717 plus autosampler automatic injector, a Waters 515 pump equipped with a C-18 column (Waters Nova-Pak C18, 3 μm, 3.9 mm × 150 cm), a BAS LC-4C electrochemical detector, and a glassy carbon electrode. The mobile phase consisted of 0.025 M citric acid, 1.7 m M 1-heptanesulfonic acid, and 10% methanol, in filtered distilled water, delivered at a flow rate of 0.8 ml/min. The final pH of 4.1 was obtained by addition of NaOH. The electrochemical potential was set at 0.8 V with respect to an Ag/AgCl reference electrode. Biogenic amine values were normalized to protein concentrations, and the results were expressed in nanograms of amine per milligram of protein. Proteins were assayed with a Micro BCA Protein Assay kit (Thermo Scientific, Rockford, Ill., USA).
DAT Autoradiography
DAT autoradiography in the striatum and the substantia nigra was performed as previously described [9] . DAT-specific binding used 20 The plasma levels of testosterone, dihydrotestosterone (DHT), 5α-androstane-3β,17β-diol (3β-diol), and PROG were measured with gas chromatography-mass spectrometry as described [25] . Plasma of 2 or 3 mice from the same group and with similar DA 304 PREG), tetrahydroprogesterone (THP, allopregnanolone), dehydroepiandrosterone (DHEA), testosterone, DHT, 5α-androstane-3α,17β-diol (3α-diol), 3β-diol, and 17β-estradiol] by liquid chromatography-tandem mass spectrometry was performed as reported [26] . One brain hemisphere was used to measure brain steroid concentrations. The mouse brain samples were analyzed individually, whereas pools of 2-3 mice from the same group and with similar DA concentrations were used in order to have enough plasma to quantify the steroid concentrations. A large number of plasma and brain samples had 17β-estradiol concentrations under the detection limit of quantification (0.02 pg/μl or pg/mg) for all the experimental groups; hence these data were not included. 
Statistical Analysis
Statistical comparisons of the data were performed with a oneway analysis of variance using Stat View 4.51 software for Macintosh Computer, followed by a post hoc analysis with Fisher's protected least significant difference test. A simple regression model was used to determine the coefficient of correlation. p < 0.05 was required for the results to be considered statistically significant.
Results

Neuroprotection Experiment 1 Dopaminergic Markers
In intact nonlesioned mice, PROG treatment had no effect on striatal DA concentrations ( fig. 1 a) and those of its metabolites DOPAC ( fig. 1 b) , 3-MT ( fig. 1 c) , and HVA ( fig. 1 d) as well as those of striatal serotonin and its metabolite 5-HIAA ( fig. 1 h, i) . Administration of MPTP decreased striatal DA concentrations (decrease of 49%; fig. 1 a) as well as DOPAC (decrease of 48%; fig. 1 b) , 3-MT (decrease of 35%; fig. 1 c) , and HVA (decrease of 45%; fig. 1 d) concentrations and increased the 3-MT/DA ratio ( fig. 1 f) . MPTP at the dose used showed specificity to the DA system, striatal serotonin and 5-HIAA concentrations revealing no significant difference between the groups ( fig. 1 h-j) . Treatment with PROG completely prevented the effect of MPTP toxicity on DA concentrations ( fig. 1 a) as well as on the increase in the 3-MT/DA ratio ( fig. 1 f) and partially the decrease in the DOPAC content ( fig. 1 b) .
PROG treatment had no effect on DAT-specific binding in the striatum of nonlesioned mice ( fig. 2 a, c) . Measures of DAT-specific binding in all regions of the striatum showed a decrease in MPTP-treated mice as compared to control values ( fig. 2 a, c) . PROG was effective in reducing the impact of MPTP toxicity on DAT-specific binding in the lateral part of the anterior striatum as well as in the medial and lateral parts of the middle striatum. No significant difference between groups was observed for DAT-specific binding in the substantia nigra pars compacta ( fig. 2 b, c) .
No statistically significant differences in VMAT2-specific binding in the striatum were observed between control mice and PROG-treated, nonlesioned mice ( fig. 3 a,  c) . MPTP-treated mice showed a decrease in VMAT2-specific binding in all the areas of the striatum measured ( fig. 3 a, b) . PROG treatment reduced MPTP toxicity as measured with VMAT2-specific binding in the medial and lateral parts of the anterior, middle, and posterior striatum. In the substantia nigra, PROG treatment did not change the VMAT2-specific binding in nonlesioned mice ( fig. 3 b, c) . Nigral VMAT2-specific binding was slightly reduced in MPTP-treated mice, whereas PROG + MPTP-treated mice were at the control levels.
Plasma Concentration of Steroids
Measures of steroid plasma levels showed that PROG treatment in intact mice induces a decrease in the levels of testosterone, DHT, and 3β-diol ( fig. 4 ) . Lower levels of the androgens testosterone, DHT, and 3β-diol were observed in MPTP-treated mice as compared to control mice. MPTP mice receiving PROG treatment had significantly higher levels of testosterone and DHT than MPTPtreated mice receiving vehicle. An increase in plasma levels of PROG was observed in MPTP mice treated with PROG.
Neuroprotection Experiment 2 Dopaminergic Markers
The administration of MPTP induced a significant decrease in the concentrations of DA (65% decrease compared to the control group; fig. 5 a) . A dose-response effect of PROG was observed when the steroid was administered after MPTP. The dose of 8 mg/kg of PROG, but not 16 mg/kg, significantly reduced the effect of MPTP, with a 53% increase in DA concentrations as compared to MPTP mice. The administration of PROG (8 mg/kg) also reduced the effect of MPTP on concentrations of DOPAC ( fig. 5 b) and on the ratio of 3-MT/ DA ( fig. 5 f) . PROG at both doses tested reduced the increase in the ratio of HVA/DA induced by MPTP ( fig. 5 g) . No significant change in striatal serotonin concentrations was observed ( fig. 5 h) . MPTP-treated mice and MPTP mice treated with PROG (all doses) had higher 5-HIAA concentrations and a superior 5-HIAA/serotonin ratio than control mice ( fig. 5 i, j) . Mice treated with 16 mg/kg of PROG had a decrease in striatal 5-HIAA concentrations as compared to MPTP-treated mice ( fig. 5 i) . Only the dose of 8 mg/kg of PROG significantly reduced the effect of MPTP on the 5-HIAA/serotonin ratio ( fig. 5 j) .
Both doses of PROG significantly decreased the effect of MPTP on DAT-specific binding in the medial and lateral parts of the anterior striatum ( fig. 6 a, c) . Increased DAT-specific binding as compared to MPTP was observed with the 8 mg/kg dose of PROG, both for the medial and lateral parts of the middle striatum. Moreover, in both the medial and lateral parts of the posterior striatum, PROG (8 mg/kg) treatment was effective in reducing the MPTP effect. In the substantia nigra pars compacta, MPTP mice treated with PROG (8 mg/kg) had DAT-specific binding at control values ( fig. 6 b, c) . A decrease in DAT-specific binding was observed in MPTP-treated mice and in mice receiving 16 mg/kg of PROG. For VMAT2-specific binding, only PROG administered at the dose of 8 mg/kg reduced MPTP toxicity in the medial and lateral parts of the anterior and middle striatum, as well as in the medial part of the posterior striatum ( fig. 7 a, c) . Moreover, in the medial part of the posterior striatum, PROG administered at 8 mg/kg reduced the MPTP effect. When mice were treated with 16 mg/kg of PROG, a decrease in the MPTP effect was observed in the lateral part of the posterior striatum. A reduction in nigral VMAT2-specific binding was observed in MPTP-treated mice and in mice treated with doses of 8 and 16 mg/kg of PROG ( fig. 7 b, c) . Plasma and Brain Concentrations of Neuroactive Steroids By liquid chromatography-tandem mass spectrometry, we next addressed whether neuroactive steroid levels in plasma and brain tissue were changed by MPTP lesion and by treatment with different doses of PROG. A schematic representation of biosynthesis pathways of steroids is presented in figure 8 .
The data obtained revealed that among PREG, PROG, and its derivatives, only DHP and ISOPREG levels were significantly affected in MPTP-treated male mice ( fig. 9 a) . In particular, these two neuroactive steroids were in- creased in plasma. PROG treatments showed a dose-dependent increase in PROG levels in plasma; assessment of PROG metabolites revealed that both doses of PROG administered decreased DHP levels as compared to MPTP-treated mice, while only the highest dose of PROG was able to significantly decrease the levels of ISOPREG. THP levels were not affected in MPTP-treated male mice, and 24 h after the last PROG treatment no change was observed ( fig. 9 a) . In brain tissue ( fig. 9 a) , the levels of all of these neuroactive steroids were unchanged in MPTP-treated male mice; however, treatment with PROG at the highest dose was able to significantly increase PREG, PROG, DHP, ISOPREG, and THP ( fig. 9 a) . Interestingly, PROG treatment at the dose of 8 mg/kg was able to decrease the levels of PREG and increase PROG and THP levels in brain tissue. Significant positive correlations were observed between plasma and brain levels of PROG, and a significant negative correlation was found between plasma and brain levels of ISOPREG ( fig. 9 b) .
As reported in figure 10 a, the levels of the testosterone metabolites DHT, 3α-diol, and 3β-diol were significantly decreased in the plasma of MPTP-treated male mice, while no change was observed for DHEA and testosterone as compared to the control group. By contrast, in brain tissue, only the levels of DHT were changed and were significantly increased ( fig. 10 a) . In brain tissue, treatment with PROG at the dose of 8 mg/kg was able to decrease the levels of DHT as compared to MPTP-treated mice, while after treatment with the highest dose, a significant increase was observed. In brain tissue, the levels of DHEA and 3β-diol were not modified in MPTP- 311 treated male mice, but affected by PROG treatment. Thus, the dose of 16 mg/kg was able to significantly decrease the levels of these two neuroactive steroids. Significant positive correlations were observed between plasma and brain levels of DHEA, as well as between plasma and brain levels of testosterone; a significant negative correlation was found between plasma and brain levels of DHT ( fig. 10 b) . Brain and plasma levels of 17β-estradiol remained low or under the detection limit in all experimental groups, showing no effect of PROG treatment (data not shown).
Discussion
The present results show that a low dose of PROG has a neuroprotective effect, and at higher doses PROG has beneficial effects on dopaminergic neurons exposed to MPTP. The present results support our previous publications on the neuroprotective effect of PROG in MPTP retired breeder mice [7, 9] . At a dose of 1 μg, PROG reduced the effect of MPTP when a moderate lesion of the nigrostriatal dopaminergic system was present (experiment 1), but had a limited effect in experiment 2 [our unpubl. results], when dopaminergic neurons had already been exposed to MPTP. A higher dose of PROG was required to observe an effect on dopaminergic markers in experiment 2; a dose of 8 mg/kg was neuroprotective, while 16 mg/kg of PROG had more limited effects.
Although data on the beneficial effect of PROG on brain trauma are abundant [27] , few studies investigated the potential protective role of PROG in dopaminergic neurons exposed to toxin-induced damage. A study in rats lesioned with 6-OHDA showed that the administration of chronic PROG (8 mg/kg) 24 h after injury increased the metabolism of striatal DA and exacerbated motor deficits induced by the lesion [19] . In contrast, others reported that the administration of high doses of PROG (4 mg/kg) 7 days after the striatal injection of 6-OHDA improved motor and cognitive deficits [20] . Although in the present study the therapeutic window of opportunity of PROG was not investigated, and PROG was administered relatively shortly after the lesion, the study on rats injured with 6-OHDA [20] suggests that the therapeutic window of opportunity of PROG is relatively wide, with benefits seen after a long period following the lesion. These data suggest that PROG could be an interesting candidate for delaying the degeneration of DA neurons.
The accumulation of PROG after its intraperitoneal administration is reported to be higher in the brain than in plasma [28] . Thus, high levels of PROG are quickly found in the brain after injection, allowing a rapid action of this steroid in the brain. PROG exerts its action by binding to two nuclear receptors, PROG receptor (PR)-A and PR-B [29] . In addition, PROG also binds to membrane PROG receptor (mPR)-α and -β [30] . PR-A, PR-B, and mPR-α are expressed in the striatum [31, 32] , while PR-A, PR-B, and mPR-β have been found in the substantia nigra [33] [34] [35] . Whereas the mechanisms of PROG action in the striatum have received little attention, PROG is reported to mediate its effect through multiple mechanisms. PROG increases the brain's mitochondrial efficiency by reducing leakage and lipid peroxidation, supporting its ability to increase the oxidative capacity of brain mitochondria and thus to reduce oxidative stress [36] . THP (allopregnanolone), an active metabolite of PROG, has antiapoptotic effects by inhibiting the opening of the permeability transition pore and inhibiting the mitochondrial release of cytochrome c [37] . In cultured neurons of the striatum, PROG blocks neuronal death that occurs by depolarization induced by opening voltage-gated calcium channels by blocking the entry of calcium in these channels [38] . This effect of PROG requires high concentrations and cannot be blocked by the use of a nuclear receptor antagonist, suggesting a mechanism independent of the activation of these receptors [38] . PROG increases the activity of Akt and ERK1/2, both major kinases involved in cell survival [12, 39] . PROG also has anti-inflammatory properties, and its action reduces the inflammatory response following brain damage [40, 41] . By the activation of nuclear receptors, PROG increases the levels of brain-derived neurotrophic factor [42] , a neurotrophic factor involved in neuroprotection and in maintaining neuron function [43] . PROG increases the expression of the mitochondrial antiapoptotic protein Bcl-2 [44] and was reported to decrease oxidative stress by increasing the levels of endogenous antioxidants such as glutathione, superoxide dismutase, and catalase [45] . PROG has active metabolites, i.e. DHP and THP, which are reported to have beneficial effects on the brain [46, 47] . The two enzymes responsible for the conversion of PROG to DHP and, subsequently, to THP, i.e. 5α-reductase and 3α-hydroxysteroid dehydrogenase, are present in the brain [48] . It is, therefore, possible that the neuroprotective effect observed in the present study is due to metabolism of PROG. Our results showed that an increase in the brain levels of PROG and THP oc-curred following PROG treatment at the doses investigated, while the brain levels of DHP and ISOPREG were only increased with 16 mg/kg of PROG. THP and ISO-PREG are modulators of GABA A receptor [49] ; it is, therefore, possible that the increase in the brain levels of THP and ISOPREG modulates GABA A receptor. A high accumulation of brain PROG and its metabolites was not associated with neuroprotective levels, since a more limited effect of PROG treatment was observed on dopaminergic markers when administered at the dose of 16 mg/kg. In support of the role of PROG metabolites in neuroprotection, several in vitro and in vivo studies have shown that blockage of 5α-reductase, the first enzyme involved in the conversion of PROG into DHP, abolishes the neuroprotective effect of PROG in various models [50] [51] [52] . Furthermore, administration of THP once weekly for 2 weeks to MPTP-treated mice is reported to restore positive cells for tyrosine hydroxylase in the substantia nigra as well as motor behavior, and to induce the generation of new positive neurons for tyrosine hydroxylase in the substantia nigra [53] . In this study, THP was administered at a time when the damage induced by MPTP is stable, that is after 7 days [54] . Thus, THP has a potent capacity for recovery and neurogenesis of tyrosine hydroxylase neurons. Nevertheless, it remains to be investigated whether the conversion of PROG to DHP and THP has a role in the neuroprotective effect of PROG in dopaminergic neurons in MPTP-treated mice; this could be done by blocking 5α-reductase activity.
High levels of PROG and its metabolites DHP and THP were found in the human brain [55] . A decrease in 5α-reductase, the enzyme responsible for the conversion of PROG to its metabolites, was observed in the substantia nigra of PD patients [56] . This reduction could account for the decreased levels of THP and DHP found in the cerebrospinal fluid of PD patients [57] . Moreover, an alteration in PROG metabolism has also been reported in a different animal model of PD [58] . Further work is needed to investigate how the decrease in PROG metabolites contributes to the degenerative process, but current data suggest that PROG could be an interesting therapeutic compound, since THP is known to modulate dopaminergic systems, to act as a positive neuromodulator of GABA A receptors, and to have neuroprotective effects [53, 59] . Future studies that compare the neuroprotective effect of PROG and THP on dopaminergic neurons could also be very informative, as THP could potentially be used instead of PROG when 5α-reductase activity is impaired, as has been observed to occur in PD patients.
MPTP is reported to induce damage to Leydig cells [60] , causing a decrease in plasma androgen levels [60, 61] , as shown in the present study. We also observed a reduction in plasma androgen levels in intact and MPTP mice treated with PROG. The effect of PROG on androgen biosynthesis is reported to be mediated by its inhibitory effect on luteinizing hormone, which is responsible for the production of testosterone by Leydig cells [62] . An increase in brain DHT was observed in MPTP-treated mice and with PROG treatment at 16 mg/kg. A previous study from our group reported a lack of a protective effect on dopaminergic markers in MPTP-treated mice receiving androgen treatment [63] , suggesting that an increase in brain androgen concentrations is not implicated in the limited protective effect of PROG observed at the dose of 16 mg/kg.
We find that changes in brain steroid levels following PROG treatment did not necessarily reflect the changes observed in plasma levels. Not only treatment with steroids, such as progesterone, results in different levels of steroids in plasma and brain; indeed, a study reported that intact male and female rodents show differences in their plasma and brain levels for some steroids, with sex differences observed [64] . Thus, measures of steroids in plasma may not always be valuable to predict their brain levels.
PROG is reported to modulate DA activity as shown by a rapid increase in striatal DA, DOPAC, and HVA concentrations in rodents [65, 66] . Thus, our results obtained in MPTP mice treated with PROG could be caused by a hormonal effect on DA synthesis or metabolism. Nevertheless, we reported that chronic treatment with PROG of intact male mice did not modulate DA and turnover as well as DAT-and VMAT2-specific binding, whereas PROG-treated MPTP mice had higher DA, DAT, and VMAT2 levels than vehicle-treated MPTP mice. Thus, the results presented here support the suggestion that the DA changes observed involve neuroprotection rather than only modulation of DA activity.
Studies in both men and women have shown the beneficial effect of PROG administration to reduce damage following traumatic brain injury [10, 11] . No side effects from the use of a high dose of PROG in the short term have been reported in patients with a traumatic brain injury. PROG is sometimes used in monotherapy to treat symptoms of menopause in women, and few side effects were observed during long-term use with low, medium, or high doses [67] . PROG represents an interesting therapeutic option for brain disease that could be used in both men and women.
In this study, we have shown that the use of a low dose of PROG had neuroprotective capacities by decreasing the toxic effects of MPTP in dopaminergic neurons. Furthermore, administration of PROG at higher doses induced protective effects on dopaminergic neurons that have already been exposed to MPTP.
